Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT07511127

Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT

Led by Ruijin Hospital · Updated on 2026-04-06

218

Participants Needed

1

Research Sites

148 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To comparing the efficacy of different durations of Maribavir treatment regimens in patients suffering from refractory CMV infection after allo-HSCT.

CONDITIONS

Official Title

Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • First allogeneic hematopoietic stem cell transplantation
  • Age 18 years or older
  • Confirmed refractory CMV infection, defined as persistent or increasing CMV levels despite at least 2 weeks of antiviral therapy, drug-resistant CMV infection with specific gene mutations, or intolerance to antiviral therapy due to severe side effects
  • Willingness to provide written informed consent and participate in the study
Not Eligible

You will not qualify if you...

  • Known allergy or hypersensitivity to any component of Maribavir
  • Active hepatitis B infection with HBV DNA level 1 × 10³ IU/mL or higher
  • Confirmed HIV infection
  • Severe impairment of major organs such as respiratory failure, heart failure, decompensated liver insufficiency, or kidney failure
  • CMV infection affecting the central nervous system
  • History of substance use disorder or chronic alcoholism that could affect study results
  • Psychiatric disorder or cognitive impairment preventing informed consent
  • Any other condition considered by the investigator to make the participant unsuitable for the trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Ruijin Hospital, Shanghai JiaoTong University School of Medicine

Shanghai, China

Actively Recruiting

Loading map...

Research Team

X

Xiaoxia Hu

CONTACT

L

Luxiang Wang

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here